Clinical Trial

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. NAFLD increases a person's risk of developing liver cancer. Liver fibrosis is the common finding of chronic liver diseases leading to reduced liver function. Lisinopril is a medication that is commonly used to treat high blood pressure. Lisinopril may help to decrease liver fibrosis. The purpose of this trial is to find out what effect, if any, lisinopril has on a patient's risk of developing liver cancer.
Protocol Amendment History 1 change
notable Enrollment reduced: 45 -> 35 participants 2026-08-15
Trial Details
NCT Number NCT04550481
Lead Sponsor Northwestern University
Collaborators: National Cancer Institute (NCI)
Conditions Hepatocellular Carcinoma, Nonalcoholic Steatohepatitis
Enrollment 35 participants
Start Date 2021-05-11
Primary Completion 2025-08-08 (estimated)
Study Completion 2026-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-14